ResMed publishes Q1 FY2027 earnings call transcript
RMD•ResMed reported quarterly revenue of $1.4 billion and non-GAAP diluted earnings per share of $2.91, up 14%. It maintained full-year revenue guidance of $5.75 billion-$5.85 billion and non-GAAP EPS guidance of $12-$12.25.
1. Quarterly results and outlook
ResMed's Oct. 29, 2026, Q1 fiscal 2027 earnings call featured CEO Michael J. Farrell, CFO Aaron Bloomer and investor-relations chief Sallilyn Schwartz. Revenue reached $1.4 billion, and non-GAAP diluted earnings per share rose 14% to $2.91. Management maintained full-year revenue guidance of $5.75 billion-$5.85 billion and non-GAAP EPS guidance of $12-$12.25.
2. Growth and margin details
Core constant-currency revenue growth guidance remains 5%-7%, with Bloomer saying the midpoint is most likely as France's fleet-renewal benefit fades. Non-GAAP gross margin was 62.5%; deferred Indiana expansion costs are expected to create a 30-basis-point sequential headwind in Q2.
